Avalyn’s Nasdaq debut raised about $300M and the stock jumped 64% to close at $29.49 as the company advances inhaled therapies for pulmonary fibrosis.

Biogen beat Q1 estimates as Leqembi sales surged 74% to $168M, but the company trimmed full‑year EPS after booking deal‑related charges tied to the Apellis purchase.

Cambridge-based Axoft says it temporarily implanted its Fleuron brain probe in a Shanghai patient and closed a $55M Series A to expand trials and scale manufacturing.

Charles Lieber, convicted in 2021, now heads i‑BRAIN in Shenzhen with a new ASML nanofab and primate infrastructure — a move that raises policy and security questions.

Baystate Health will transition Mercy Medical Center in Springfield into its system under a definitive agreement meant to stabilize operations. The move is subject to regulatory approval and the transition is slated for Nov. 1, 2026.

Cambridge-based Hemab filed to raise $212M in a Nasdaq IPO to advance clinical programs for rare bleeding disorders. The S-1 outlines uses for sutacimig and HMB-002.

A Somerville randomized trial found one month of HEPA filtration sped up executive function by about 12% for adults 40+, though researchers call the result preliminary.

Large phase‑3 trials show AD109, a once‑nightly pill, cut sleep‑apnea severity by about half; dry mouth and insomnia were common and regulators will review safety.

BU researchers found that zebra finch newborn neurons tunnel through mature tissue, offering a tangible clue to why adult neurogenesis is limited in humans. The finding reframes how scientists think about plasticity versus memory stability.

Tutor Intelligence's new Watertown hub trains robots on thousands of hours of real-world work and positions the town at the center of industrial AI. The operation raises questions about automation and local jobs.

Interim REMAIN‑1 results suggest a one‑time endoscopic "gut reset" can help maintain weight after stopping GLP‑1 drugs. Topline pivotal data are expected in Q4 2026.

Tufts Medical Center won approval to begin living‑donor liver transplants, adding a new route for patients and donors in Boston. The program builds on the hospital’s revived liver services.

Framingham startup Tortugas raised $106M to advance four Phase 2 brain‑drug programs, including schizophrenia and tinnitus candidates licensed from Eisai and Hansoh. The funds will bankroll completion of key midstage trials.